• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一个关于萨拉米切片的案例研究:度洛西汀治疗抑郁症的汇总分析。

A case study of salami slicing: pooled analyses of duloxetine for depression.

机构信息

Department of Psychology, Metropolitan State University, St. Paul, Minn. 55108, USA.

出版信息

Psychother Psychosom. 2010;79(2):97-106. doi: 10.1159/000270917. Epub 2009 Dec 24.

DOI:10.1159/000270917
PMID:20051707
Abstract

BACKGROUND

Publishing separate, yet very similar pieces of a single dataset across multiple papers is known as 'salami slicing'. This practice may be motivated by researchers wishing to increase their publication counts and by the desire to increase exposure of their findings. 'Salami slicing' may also be used by the drug industry to help widely disseminate positive findings regarding its products. Journal editors across many scientific disciplines have bemoaned such duplicative publications on several occasions. However, little research has been conducted on the frequency of such publication practices, and findings have been inconsistent. No research has investigated whether 'salami slicing' may also occur in publications presenting results from pooled analyses of clinical trials.

METHODS

We examined the scientific literature on duloxetine as a treatment for depression, examining how data from clinical trials were reported across 43 pooled analyses.

RESULTS

The vast majority of pooled analyses (88%) had at least one author who was employed by the manufacturer of duloxetine. Several pooled analyses based on highly overlapping clinical trials presented efficacy and safety data that did not answer unique research questions, and thus appeared to qualify as salami publications. Six clinical trials had their data utilized as part of 20 or more separately published pooled analyses.

CONCLUSIONS

Such redundant publications add little to scientific understanding and represent a poor use of peer reviewer and editorial resources.

摘要

背景

将单个数据集的单独但非常相似的部分分别发表在多篇论文中,这种做法被称为“切片式发表”。这种做法可能是由于研究人员希望增加他们的发表数量,也可能是因为他们希望增加研究结果的曝光度。制药行业也可能会采用这种做法,以帮助广泛传播其产品的阳性研究结果。许多科学学科的期刊编辑都曾多次谴责这种重复发表的行为。然而,对于这种发表做法的频率,研究甚少,且结果不一致。尚未有研究调查“切片式发表”是否也可能发生在汇集临床试验结果的出版物中。

方法

我们检查了度洛西汀作为治疗抑郁症的科学文献,研究了 43 项汇集分析中临床试验数据的报告方式。

结果

绝大多数汇集分析(88%)至少有一位作者受度洛西汀制造商雇佣。有几个基于高度重叠的临床试验的汇集分析提出了疗效和安全性数据,这些数据没有回答独特的研究问题,因此似乎符合“切片式发表”的标准。六个临床试验的数据被用于 20 个以上单独发表的汇集分析中。

结论

这种重复发表对科学理解几乎没有增加,是对同行评审和编辑资源的浪费。

相似文献

1
A case study of salami slicing: pooled analyses of duloxetine for depression.一个关于萨拉米切片的案例研究:度洛西汀治疗抑郁症的汇总分析。
Psychother Psychosom. 2010;79(2):97-106. doi: 10.1159/000270917. Epub 2009 Dec 24.
2
Anxiety does not predict response to duloxetine in major depression: results of a pooled analysis of individual patient data from 11 placebo-controlled trials.焦虑并不能预测度洛西汀治疗重度抑郁症的疗效:来自 11 项安慰剂对照试验的个体患者数据汇总分析的结果。
Depress Anxiety. 2010;27(1):12-8. doi: 10.1002/da.20632.
3
Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder.重度抑郁症患者突然停用度洛西汀治疗后的症状。
J Affect Disord. 2005 Dec;89(1-3):207-12. doi: 10.1016/j.jad.2005.09.003. Epub 2005 Nov 2.
4
Duloxetine in the treatment of major depressive disorder: comparisons of safety and tolerability in male and female patients.度洛西汀治疗重度抑郁症:男性和女性患者安全性及耐受性比较
J Affect Disord. 2006 Aug;94(1-3):183-9. doi: 10.1016/j.jad.2006.04.006. Epub 2006 Jun 14.
5
Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.度洛西汀50毫克/天和100毫克/天治疗重度抑郁症:一项为期8周的III期多中心随机双盲安慰剂对照平行组试验及三项研究的事后汇总分析。
Clin Ther. 2009 Jun;31 Pt 1:1405-23. doi: 10.1016/j.clinthera.2009.07.006.
6
Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression.度洛西汀每日一次60毫克治疗重度抑郁症的疗效、安全性及耐受性
Curr Med Res Opin. 2005 Mar;21(3):345-56. doi: 10.1185/030079905X30680.
7
Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials.度洛西汀治疗重度抑郁症的安全性和耐受性:八项安慰剂对照临床试验汇总数据的分析
Hum Psychopharmacol. 2005 Jul;20(5):327-41. doi: 10.1002/hup.696.
8
A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.度洛西汀与文拉法辛治疗重度抑郁症患者的随机双盲对照研究
J Psychiatr Res. 2008 Jan;42(1):22-34. doi: 10.1016/j.jpsychires.2007.01.008. Epub 2007 Apr 18.
9
Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.度洛西汀与艾司西酞普兰及安慰剂对比:一项针对重度抑郁症患者的8个月双盲试验。
Curr Med Res Opin. 2007 Jun;23(6):1303-18. doi: 10.1185/030079907X188107. Epub 2007 Apr 27.
10
Long-term tolerability and effectiveness of duloxetine in the treatment of major depressive disorder.度洛西汀治疗重度抑郁症的长期耐受性及有效性
Depress Anxiety. 2008;25(5):E1-8. doi: 10.1002/da.20339.

引用本文的文献

1
Credibility revolution: pursuing a balanced and sustainable approach, without dogmas, without magic elixirs.可信度革命:追求一种平衡且可持续的方法,不抱教条,没有万灵药。
Front Psychol. 2025 Apr 16;16:1581160. doi: 10.3389/fpsyg.2025.1581160. eCollection 2025.
2
Vibration of effect in more than 16 000 pooled analyses of individual participant data from 12 randomised controlled trials comparing canagliflozin and placebo for type 2 diabetes mellitus: multiverse analysis.在12项比较卡格列净与安慰剂治疗2型糖尿病的随机对照试验中,对超过16000份个体参与者数据进行汇总分析的效应振动:多变量分析。
BMJ Med. 2022 Sep 14;1(1):e000154. doi: 10.1136/bmjmed-2022-000154. eCollection 2022.
3
Denying the accusation of plagiarism: power relations at play in dictating plagiarism as academic misconduct.
否认抄袭指控:在将抄袭认定为学术不端行为中起作用的权力关系。
High Educ (Dordr). 2023;85(5):979-997. doi: 10.1007/s10734-022-00875-z. Epub 2022 May 28.
4
The Impact of Industry Funding on Randomized Controlled Trials of Biologic Therapies.行业资金对生物疗法随机对照试验的影响。
Medicines (Basel). 2022 Feb 28;9(3):18. doi: 10.3390/medicines9030018.
5
Hiding negative trials by pooling them: a secondary analysis of pooled-trials publication bias in FDA-registered antidepressant trials.通过合并来隐藏负面试验:对 FDA 注册抗抑郁药试验中合并试验发表偏倚的二次分析。
Psychol Med. 2019 Sep;49(12):2020-2026. doi: 10.1017/S0033291718002805. Epub 2018 Sep 28.
6
Evidence of selective reporting bias in hematology journals: A systematic review.血液学杂志中选择性报告偏倚的证据:一项系统评价。
PLoS One. 2017 Jun 1;12(6):e0178379. doi: 10.1371/journal.pone.0178379. eCollection 2017.
7
Publication bias, with a focus on psychiatry: causes and solutions.发表偏倚,以精神病学为例:原因与解决方法。
CNS Drugs. 2013 Jun;27(6):457-68. doi: 10.1007/s40263-013-0067-9.
8
Legitimate division of large data sets, salami slicing and dual publication, where does a fraud begin?大数据集的合理划分、“切香肠”式发表和一稿多投,欺诈从何而起?
Knee Surg Sports Traumatol Arthrosc. 2013 Apr;21(4):751-2. doi: 10.1007/s00167-013-2413-3.
9
Promoting transparency in pharmaceutical industry-sponsored research.促进制药行业赞助研究的透明度。
Am J Public Health. 2012 Jan;102(1):72-80. doi: 10.2105/AJPH.2011.300187. Epub 2011 Nov 28.
10
Those who have the gold make the evidence: how the pharmaceutical industry biases the outcomes of clinical trials of medications.谁有钱,谁就有证据:制药行业如何影响药物临床试验结果的偏倚。
Sci Eng Ethics. 2012 Jun;18(2):247-61. doi: 10.1007/s11948-011-9265-3. Epub 2011 Feb 15.